| Eye Care, Inc | |
|
5848 Line Ave, Shreveport, LA 71106-1532 | |
| (318) 865-0017 | |
| (318) 868-4738 |
| Full Name | Eye Care, Inc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 5848 Line Ave, Shreveport, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295807642 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 963-247T (Louisiana) | Primary |
| Provider Name | Alisa K Brogden |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1598878860 PECOS PAC ID: 6103928478 Enrollment ID: I20070217000045 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
| Provider Name | Michael D Pickering |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1114022175 PECOS PAC ID: 2769496637 Enrollment ID: I20100330001296 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
| Provider Name | Carla Carter |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1902184369 PECOS PAC ID: 3870765605 Enrollment ID: I20111020000246 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
| Provider Name | Tiffany M Griffin |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1730468851 PECOS PAC ID: 4486816709 Enrollment ID: I20140507001362 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
| Provider Name | Dea Orana |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1316614365 PECOS PAC ID: 7810387206 Enrollment ID: I20211129000286 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Eye Care, Inc 5848 Line Ave, Shreveport, LA 71106-1532 Ph: (318) 865-0017 | Eye Care, Inc 5848 Line Ave, Shreveport, LA 71106-1532 Ph: (318) 865-0017 |
News Archive
A set of 7 symptoms, considered together, can be used to maximize detection of COVID-19 in the community, according to a new paper published this week in PLOS Medicine by Marc Chadeau-Hyam and Paul Elliott of Imperial College London, UK, and colleagues.
Every day, our gut comes in contact with bacteria, inducing an inflammatory response that is tolerated and controlled. Sometimes the control of inflammation is lost and this can lead to inflammatory bowel disease that may predispose to colon cancer.
A new report issued today by the Centers for Disease Control and Prevention showed a significant decrease in certain infections over the past nine years. The report found that central line associated bloodstream infections occurring in hospital intensive care units dropped by 58 percent between 2001 and 2009.
Arteriocyte, a leading biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts announced today approval from the Food and Drug Administration (FDA) to initiate a Phase I clinical trial using its Magellan System technology in the treatment of thermal burn wounds.
For the first time, the UNC School of Medicine lab of Jonathan Schisler, MS, PhD, linked the specific biochemical changes to a protein called CHIP to specific disease characteristics of patients with a wide range of rare disorders.
› Verified 6 days ago
Sam R Silverblatt, Od Apmc Optometrist Medicare: Medicare Enrolled Practice Location: 1803 E 70th St, Shreveport, LA 71105 Phone: 318-798-4000 Fax: 318-798-4001 | |
Dr. Christine M Davis, OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 955 Pierremont Rd Ste 400, Shreveport, LA 71106 Phone: 318-868-6118 Fax: 318-666-9927 | |
Look Eyecare Llc Optometrist Medicare: Medicare Enrolled Practice Location: 5848 Line Ave, Shreveport, LA 71106 Phone: 318-865-0017 | |
Lusk Eye Specialists, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 451 Ashley Ridge Blvd, Shreveport, LA 71106 Phone: 318-222-5555 Fax: 318-222-6414 | |
Dr. Bradly Kendall Larson, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8889 Jewella Ave Ste C, Shreveport, LA 71118 Phone: 318-686-5227 Fax: 381-686-5283 | |
Weston Whitworth, OD Optometrist Medicare: Medicare Enrolled Practice Location: 8889 Jewella Ave, Shreveport, LA 71118 Phone: 318-686-5227 | |
Dr. Michael David Pickering, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5848 Line Ave, Shreveport, LA 71106 Phone: 318-865-0017 Fax: 318-868-4738 |